Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Clot-Removing device shield the Brain's thinking power after stroke?

NCT ID NCT05531461

Disease control Sponsor: Rapid Medical Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study looks at whether successfully restoring blood flow in the brain using the Tigertriever device, a tool that removes clots during a stroke, may also help protect cognitive abilities like memory and attention. Researchers will follow 424 adults aged 18 to 75 who had a large-vessel occlusion stroke and were treated with Tigertriever as the first-line therapy. They will compare thinking and memory scores taken shortly after treatment with those at 180 days to see if good blood flow restoration is linked to better cognitive outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tigertriever, a stent-retriever device used to remove blood clots in the brain during a stroke
What this could lead to
If successful, this could show that using Tigertriever to restore blood flow after a stroke may help preserve or improve cognitive function, such as memory and thinking.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Cognitive improvement may vary widely, and results may not apply to all stroke patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 424 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The COGNITIVE Study will include male or female subjects age 18-75 who present with LVO and treated with the Tigertriever as indicated per approved IFU.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as indicated per the approved IFU. 2. Tigertriever was used as the first line treatment in the target vessel. 3. A signed informed consent. 4. Age 18-75 years (inclusive). 5. No known significant pre-stroke disability (pre-stroke mRS 0 or 1). Exclusion Criteria: 1. Use of any other IA recanalization device prior to the Tigertriever in the target vessel, including aspiration catheter. 2. Evidence of acute brain hemorrhage on CT and/or MRI at admission. 3. Prior hemorrhage, stroke, thrombolysis, and/or endovascular therapy in the last 3 months. 4. Probable cerebral amyloid angiopathy. 5. Pre-stroke diagnosed dementia and/or prescribed cholinesterase inhibitors. 6. Pre-stroke diagnosed and/or currently treated major depression. 7. Pre-stroke learning or intellectual disability. 8. Anticipated inability to obtain 6-month follow-up assessments. \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Large vessel occlusion stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

large artery stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Corewell Health Research Institute

    RECRUITING

    Grand Rapids, Michigan, 49503, United States

  • University of California

    RECRUITING

    Los Angeles, California, 90095, United States

  • Westchester Medical Center

    RECRUITING

    New York, New York, 10595, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.